Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
death D28 | 1.00 [0.92, 1.08] | | < 1 | | 5% | 16 studies (19/-) | 51.6 % | some concern | low | moderate | crucial | - |
death or transfer to ICU | 1.09 [0.99, 1.20] | | < 1 | | 0% | 1 study (2/-) | 4.0 % | NA | not evaluable | | crucial | - |
deaths | 0.98 [0.93, 1.03] | | < 1 | | 0% | 54 studies (79/-) | 82.1 % | some concern | critical | moderate | crucial | - |
deaths (time to event analysis only) | 0.93 [0.84, 1.04] | | < 1 | | 43% | 13 studies (13/-) | 89.9 % | some concern | critical | moderate | crucial | - |
clinical deterioration | 1.00 [0.79, 1.27] | | < 1 | | 19% | 11 studies (16/-) | 49.4 % | some concern | low | moderate | important | - |
clinical improvement | 1.19 [1.01, 1.40] | | > 1 | | 65% | 19 studies (23/-) | 98.1 % | some concern | low | moderate | important | - |
clinical improvement (14-day) | 1.11 [0.94, 1.30] | | > 1 | | 47% | 19 studies (19/-) | 89.0 % | some concern | low | moderate | important | - |
clinical improvement (21-day) | 2.09 [0.04, 119.96] | | > 1 | | 0% | 1 study (1/-) | 63.7 % | NA | not evaluable | | important | - |
clinical improvement (28-day) | 1.24 [1.03, 1.50] | | > 1 | | 54% | 9 studies (9/-) | 98.8 % | some concern | not evaluable | moderate | important | - |
clinical improvement (7-day) | 1.22 [1.02, 1.46] | | > 1 | | 53% | 13 studies (15/-) | 98.6 % | some concern | critical | moderate | important | - |
clinical improvement (time to event analysis only) | 1.19 [1.04, 1.35] | | > 1 | | 63% | 15 studies (18/-) | 99.5 % | some concern | low | moderate | important | - |
death or ventilation | 1.02 [0.95, 1.10] | | < 1 | | 14% | 9 studies (9/-) | 27.9 % | some concern | not evaluable | moderate | important | - |
hospital discharge | 0.99 [0.89, 1.10] | | > 1 | | 55% | 13 studies (17/-) | 45.8 % | some concern | low | moderate | important | - |
hospitalization | 0.25 [0.08, 0.83] | | < 1 | | 0% | 2 studies (2/-) | 98.8 % | NA | not evaluable | | important | - |
mechanical ventilation | 0.91 [0.72, 1.15] | | < 1 | | 45% | 20 studies (24/-) | 78.5 % | some concern | low | moderate | important | - |
mechanical ventilation (time to event analysis only) | 0.06 [0.01, 0.83] | | < 1 | | 0% | 1 study (1/-) | 98.2 % | NA | not evaluable | | important | - |
radiologic improvement (14-day) | 1.22 [0.77, 1.92] | | > 1 | | 27% | 5 studies (5/-) | 80.3 % | some concern | not evaluable | moderate | important | - |
radiologic improvement (7-day) | 0.22 [0.03, 1.57] | | > 1 | | 48% | 4 studies (5/-) | 6.6 % | some concern | not evaluable | moderate | important | - |
viral clearance | 1.54 [1.07, 2.20] | | > 1 | | 71% | 12 studies (18/-) | 99.0 % | some concern | low | moderate | important | - |
viral clearance (time to event analysis only) | 1.69 [1.02, 2.78] | | > 1 | | 72% | 3 studies (8/-) | 97.9 % | some concern | not evaluable | moderate | important | - |
viral clearance by day 14 | 1.01 [0.95, 1.07] | | > 1 | | 0% | 10 studies (12/-) | 61.9 % | some concern | low | moderate | important | - |
viral clearance by day 7 | 1.01 [0.84, 1.23] | | > 1 | | 31% | 11 studies (14/-) | 55.6 % | some concern | low | moderate | important | - |
ICU admission | 0.96 [0.80, 1.14] | | < 1 | | 0% | 13 studies (15/-) | 68.3 % | some concern | low | moderate | non important | - |
off oxygenation | 0.98 [0.64, 1.51] | | > 1 | | 0% | 1 study (1/-) | 46.4 % | NA | not evaluable | | non important | - |
recovery | 1.04 [0.91, 1.20] | | > 1 | | 53% | 6 studies (6/-) | 72.3 % | some concern | not evaluable | moderate | non important | - |
severe COVID-19 occurrence | 0.30 [0.07, 1.27] | | < 1 | | 0% | 1 study (1/-) | 94.9 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
AE leading to drug discontinuation | 2.43 [0.79, 7.45] | | < 1 | | 0% | 1 study (1/-) | 6.0 % | NA | not evaluable | | important | - |
cardiac arrest | 1.92 [0.35, 10.49] | | < 1 | | 0% | 1 study (1/-) | 22.7 % | NA | not evaluable | | important | - |
related SAE (TRSAE) | 1.24 [0.50, 3.11] | | < 1 | | 0% | 1 study (1/-) | 32.0 % | NA | not evaluable | | important | - |
serious adverse events | 0.85 [0.71, 1.01] | | < 1 | | 0% | 22 studies (23/-) | 96.8 % | some concern | critical | moderate | important | - |
abnormal ECG findings | 1.50 [0.88, 2.57] | | < 1 | | 0% | 1 study (-/1) | 7.0 % | NA | not evaluable | | non important | - |
acute kidney injury | 1.18 [0.44, 3.18] | | < 1 | | 0% | 1 study (1/-) | 37.2 % | NA | not evaluable | | non important | - |
adverse events | 1.77 [1.31, 2.38] | | < 1 | | 68% | 18 studies (24/-) | 0.0 % | some concern | low | moderate | non important | - |
arrhythmia | 0.91 [0.72, 1.15] | | < 1 | | 0% | 3 studies (3/-) | 78.1 % | some concern | not evaluable | moderate | non important | - |
deep vein thrombosis | 0.62 [0.23, 1.64] | | < 1 | | 0% | 2 studies (2/-) | 83.1 % | some concern | not evaluable | moderate | non important | - |
elevated liver enzymes | 0.95 [0.29, 3.10] | | < 1 | | 84% | 3 studies (3/-) | 53.6 % | some concern | not evaluable | moderate | non important | - |
hyperbilirubinemia | 0.97 [0.48, 1.93] | | < 1 | | 0% | 2 studies (2/-) | 53.8 % | low | not evaluable | high | non important | - |
long QT | 2.39 [0.24, 23.87] | | < 1 | | 80% | 2 studies (2/-) | 23.0 % | some concern | not evaluable | moderate | non important | - |
pulmonary embolism | 0.82 [0.20, 3.29] | | < 1 | | 0% | 2 studies (2/-) | 61.1 % | some concern | not evaluable | moderate | non important | - |
renal impairment | 1.26 [0.95, 1.67] | | < 1 | | 0% | 4 studies (4/-) | 5.6 % | some concern | not evaluable | moderate | non important | - |
serious adverse events (SAE), any | 0.50 [0.32, 0.79] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | non important | - |
severe adverse events | 1.10 [0.07, 18.09] | | < 1 | | 0% | 2 studies (2/-) | 47.4 % | high | not evaluable | low | non important | - |
AE of interest endpoints 00 |
Thromboembolic events | 0.89 [0.31, 2.55] | | < 1 | | 0% | 1 study (1/-) | 58.6 % | NA | not evaluable | | non important | - |